drugset / Trial / NCT00463437

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

NCT00463437

Phase 3 Completed 1437 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK1024850A at 11 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined and meningococcal serogroup C (MenC) or combined meningococcal serogroup C and Haemophilus influenzae type b (Hib-MenC) vaccine. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00334334).

Timeline

Start
2007-04-25
Primary completion
2008-01-21
Completion
2008-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Adacel Vaccine Intramuscular
Subject GSK1024850A Vaccine Intramuscular
Subject Infanrix IPV Vaccine Intramuscular
Subject Infanrix hexa Vaccine Intramuscular
Subject Meningitec Vaccine Intramuscular
Subject Menitorix Vaccine Intramuscular
Subject NeisVac-C Vaccine Intramuscular
Subject Pediarix Vaccine Intramuscular
Comparator Prevnar 13 Vaccine Intramuscular